Biora Therapeutics, Inc. (BIORQ)

OTCMKTS · Delayed Price · Currency is USD
0.000001
0.00 (0.00%)
At close: Apr 24, 2026
Market Cap4.00 -100.0%
Revenue (ttm)892.00K +4,855.6%
Net Income-31.54M
EPS-10.46
Shares Out4.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume168
Average Volume2,260
Open0.000001
Previous Closen/a
Day's Range0.000001 - 0.000001
52-Week Range0.000001 - 0.3400
Beta5.31
RSI28.79
Earnings Daten/a

About Biora Therapeutics

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 58
Stock Exchange OTCMKTS
Ticker Symbol BIORQ
Full Company Profile

Financial Performance

In 2023, Biora Therapeutics's revenue was $4,000, a decrease of -98.69% compared to the previous year's $305,000. Losses were -$124.12 million, 225.3% more than in 2022.

Financial Statements

News

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Testing in advanced animal model planned in Q4 f or smaller, 00-size BioJet device with largest capacity of any ingestible injectable

1 year ago - GlobeNewsWire

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide...

1 year ago - GlobeNewsWire

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreemen...

1 year ago - GlobeNewsWire

Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting

Expanded collaborations to support rapid testing in advanced animal models in Q4 2024 Expanded collaborations to support rapid testing in advanced animal models in Q4 2024

1 year ago - GlobeNewsWire

Biora Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Two innovative drug-device platforms were highlighted: NaviCap, which showed strong phase I results for targeted ulcerative colitis therapy, and BioJet, advancing needle-free biologic delivery with ac...

1 year ago - Transcripts

Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that company leadership will participate in ...

1 year ago - GlobeNewsWire

Biora Therapeutics Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Two proprietary platforms enable targeted and systemic oral drug delivery, with NaviCap showing strong phase I results in UC and BioJet advancing through major pharma collaborations. Next steps includ...

1 year ago - Transcripts

Biora Therapeutics Earnings Call Transcript: Q2 2024

Q2 2024 saw successful Phase 1 results for BT-600, strong progress with BioJet, and a $16M capital raise. BioJet achieved ~40% bioavailability, and partnership talks with major pharma are nearing comp...

1 year ago - Transcripts

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan

1 year ago - GlobeNewsWire

Biora Therapeutics Announces Funding Agreement with Existing Investors

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced the signing of financing agreements with its...

1 year ago - GlobeNewsWire

Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide...

1 year ago - GlobeNewsWire

Biora Therapeutics Transcript: Study Update

Phase I results for BT-600 using the NaviCap platform showed precise, pancolonic delivery of tofacitinib with significantly reduced systemic exposure and strong safety in healthy volunteers. These fin...

1 year ago - Transcripts

Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical dat...

2 years ago - GlobeNewsWire

Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024

Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.

2 years ago - GlobeNewsWire

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented a...

2 years ago - GlobeNewsWire

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and ...

2 years ago - GlobeNewsWire

Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024

SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on...

2 years ago - GlobeNewsWire

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (N...

2 years ago - GlobeNewsWire

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent relate...

2 years ago - GlobeNewsWire

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no saf...

2 years ago - GlobeNewsWire

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously annou...

2 years ago - GlobeNewsWire

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive...

2 years ago - GlobeNewsWire

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial. Management to host conference call today at 4:30 PM ET.

2 years ago - GlobeNewsWire